Citations

Clear

2429 citation(s) found for "Shah, SS".

Investigation of Patient With Monoclonal Gammopathy of Thrombotic Significance Unmasks New Type of Platelet-Activating Anti-Platelet Factor 4 Antibody
Kanack, Adam J. , Shah, Surbhi , Padmanabhan, Anand

Mayo Clinic

The Hematologist | March 4, 2025 | Volume: 22 | Issue: 2 | Pages: No page available

10.1182/hem.v22.2.2025213 Get It

Real-word utility of procalcitonin in patients hospitalized with community-acquired pneumonia: A matched cohort study
Ilges, Dan , Kosaski, Dylan L. , Seville, Maria Teresa , McGary, Alyssa , O’Horo, John C. , Snozek, Christine L.H. , Stevens, Ryan W. , Shah, Aditya , Kosaski, Dylan , Snozek, Christine L , O'Horo, John C , Stevens, Ryan W , Seville, Maria Teresa , Ilges, Dan

Mayo Clinic

Infection Control & Hospital Epidemiology | February 28, 2025 | Volume: 46 | Issue: 5 | Pages: 519-525

10.1017/ice.2025.35 | PMID 40017121 Get It

Abstract Objective: To retrospectively observe procalcitonin (PCT) and antibiotic ordering practices in patients hospitalized with community-acquired pneumonia (CAP). Design: Retrospective, exact matched, multicenter cohort study from October 1, 2018 – March 31, 2023. Setting: All hospitals across the Mayo Clinic Enterprise. Participants: Adult patients with CAP, identified using pneumonia diagnosis codes and receipt of systemic antibiotics with an indication of “respiratory tract infection” within 48 hours of hospitalization. Methods: PCT testing within the first 7 days of hospitalization was compared to non-PCT care (nPCT). The primary outcomes were treatment duration, antibiotic days of therapy (DOT), and length of stay (LOS). Results: 15364 patients met inclusion criteria. PCT testing occurred in 42.4% (6515/15364) of encounters, totaling 8214 PCT results. 12880 unique patient encounters were matched 1:1, 6440 in each group. Treatment duration was longer in the PCT group compared to the nPCT group (5.1 vs 4.6 days, respectively, P < 0.001). Patients in the PCT group also received more DOT (8.6 vs 7.6 DOT, P < 0.001) and had a longer LOS (6.8 vs 5.9 days, P < 0.001), respectively. There was no difference in 30-day all-cause mortality or C. difficile infection between groups. In a sensitivity analysis of nPCT patients compared to those with a peak value <0.25 ng/mL (i.e. normal result) there was no difference in treatment duration (4.6 days nPCT vs 4.7 days normal PCT, P = 0.104) or LOS (5.9 days nPCT vs 6.0 days normal PCT, P = 0.134). Conclusion: PCT testing in patients hospitalized with CAP was not associated with reduced antimicrobial utilization, LOS, or 30-day all-cause mortality.
Use and safety of corticosteroid injections in joints and musculoskeletal soft tissue: guidelines from the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, the American Society of Interventional Pain Physici
Benzon, Honorio T. , Provenzano, David , Nagpal, Ameet , Souza, Dmitri , Eckmann, Maxim , Nelson, Ariana M. , Mina, Maged, Elmofty, Dalia , Pino, Carlos A. , Rana, Maunak V., Shah, Shalini , Stout, Alison , Smith, Elizabeth Reichert , Hirsch, Joshua A , Schneider, Byron J. , Manchikanti, Laxmaiah , Maus, Timothy P. , Rivera, Jessica , FitzGerald, John , Provenzano, David Anthony , Chadwick, Andrea , Doshi, Tina L , Pino, Carlos A , Shankar, Hariharan , Cohen, Steven P , Narouze, Samer , Shanthanna, Harsha , Hunt, Christine , Benzon, Honorio T , Nagpal, Ameet S , FitzGerald, John D , Nelson, Ariana M , Abd-Elsayed, Alaa A , Doshi, Tina L , Shankar, Hariharan , Smith, Elizabeth, Abdi, Salahadin , Cohen, Steven P. , Narouze, Samer , Shanthanna, Harsha , Wasan, Ajay D. , Hoang, Thanh D , Rivera, Jessica

Mayo Clinic

Regional Anesthesia & Pain Medicine | February 27, 2025 | Volume: 51 | Issue: 7 | Pages: 746-773

10.1136/rapm-2024-105656 | PMID 40015722 Get It

Background Intra-articular corticosteroid (IACS) injection and peri-articular corticosteroid injection are commonly used to treat musculoskeletal conditions. Results vary by musculoskeletal region, but most studies report short-term benefit with mixed results on long-term relief. Publications showed adverse events from single corticosteroid injections. Recommended effective doses were lower than those currently used by clinicians. Methods Development of the practice guideline for joint injections was approved by the Board of Directors of the American Society of Regional Anesthesia and Pain Medicine and the participating societies. A Corticosteroid Safety Work Group coordinated the development of three guidelines: peripheral nerve blocks and trigger points; joints; and neuraxial, facet, and sacroiliac joint injections. The topics included safety of the technique in relation to landmark-guided, ultrasound-guided, or radiology-aided injections; effect of the addition of the corticosteroid on the efficacy of the injectate; and adverse events related to the injection. Experts on the topics were assigned to extensively review the literature and initially develop consensus statements and recommendations. A modified version of the US Preventive Services Task Force grading of evidence and strength of recommendation was followed. A modified Delphi process was adhered to in arriving at a consensus. Results This guideline focuses on the safety and efficacy of corticosteroid joint injections for managing joint chronic pain in adults. The joints that were addressed included the shoulder, elbow, hand, wrist, hip, knee, and small joints of the hands and feet. All the statements and recommendations were approved by all participants and the Board of Directors of the participating societies after four rounds of discussion. There is little evidence to guide the selection of one corticosteroid over another. Ultrasound guidance increases the accuracy of injections and reduces procedural pain. A dose of 20 mg triamcinolone is as effective as 40 mg for both shoulder IACS and subacromial subdeltoid bursa corticosteroid injections. The commonly used dose for hip IACS is 40 mg triamcinolone or methylprednisolone. Triamcinolone 40 mg is as effective as 80 mg for knee IACS. Overall, IACS injections result in short-term pain relief from a few weeks to a few months. The adverse events include an increase in blood glucose, adrenal suppression, detrimental effect on cartilage lining the joint, reduction of bone mineral density, and postoperative joint infection. Conclusions In this practice guideline, we provided specific recommendations on the role of corticosteroids in joint, bursa, and peritendon injections for musculoskeletal pain.
Case 338
Shah, Amar , Zulfiqar, Maria , Zulfiqar, Maria , Shah, Amar S

Mayo Clinic

Radiology | February 25, 2025 | Volume: 314 | Issue: 2 | Pages: No page available

10.1148/radiol.242727 | PMID 39998378 Get It

History A 25-year-old female patient presented to the emergency department with worsening abdominal discomfort over the past 2–3 months. The patient had not experienced fever, chills, or dysuria. Past medical history was notable for two completed pregnancies; otherwise, there was no pertinent medical history or family history. At physical examination, the patient was uncomfortable but not in acute distress. There was tenderness to palpation in the right upper quadrant and epigastric region, but no rebound tenderness or guarding. Vital signs were blood pressure of 141/85 mm Hg, pulse rate of 91/min, and temperature of 37.2 °C. The serum β–human chorionic gonadotropin test result was negative for pregnancy, and urinalysis showed no leukocyte esterase or nitrites. Routine blood investigations, including white blood cell count, were within normal limits. Initial evaluation with contrast-enhanced CT of the abdomen and pelvis was performed ( Fig 1 ), followed by MRI of the abdomen without and with intravenous contrast material ( Fig 2 ).
Abstract B034: The immune checkpoint molecule B7-H3 is a driver of tumor immune exclusion by mediating TGF-β activation
Lavoie, Roxane R. , Korleski, Jack , Kim, Yohan, Farrell, Ava, Harper, Kelly , Charbonneau, Martine , Frank, Igor, Gupta, Sounak , Cheville, John C. , Orme, Jacob J. , Boorjian, Stephen A. , Shah, P., Kwon, Eugene D., Lucien, Fabrice , Wootla, Bharath , Wang, Liguo , Dubois, Claire M. , Park, Sean S. , Dong, Haidong

Mayo Clinic

Cancer Immunology Research | February 23, 2025 | Volume: 13 | Issue: 2_Supplement | Pages: B034-B034

10.1158/2326-6074.io2025-b034 Get It

Abstract Addressing the limited responsiveness to immune checkpoint blockade (ICB) in human cancers remains a critical challenge. Efforts over the past two decades have primarily focused on enhancing CD8 T cell function and preventing their exhaustion. However, less attention has been given to understanding the molecular mechanisms that contribute to the immunosuppressive tumor microenvironment (TME), which impedes CD8 T cell infiltration and fosters ICB resistance. The TME in ICB-resistant tumors is characterized by Transforming Growth Factor beta (TGF-β) cytokine signaling, leading to a fibrotic extracellular matrix (ECM) and the accumulation of immunosuppressive fibroblasts and myeloid cells. These features hinder CD8 T cell penetration, thereby promoting immune escape. The immune checkpoint molecule B7-H3, overexpressed in ICB-resistant cancers, has been linked to impaired CD8 T cell infiltration and poor prognosis. However, the molecular mechanisms governing B7-H3 function remain poorly understood. We investigated the relationship between B7-H3 gene expression and ICB response using transcriptomic data from two randomized phase 3 trials (IMvigor010 and IMvigor210). Bulk RNAseq data, tissue staining, and spectral flow cytometry were used to characterize the TME composition of B7-H3 high and low tumors. Multi-omic profiling of tumor cell lines with manipulated B7-H3 expression was performed to identify downstream targets of B7-H3. Syngeneic mouse tumor models were used to assess the impact of B7-H3 on tumor growth and antitumor immunity. High B7-H3 expression was associated with shorter overall survival in both IMvigor010 (HR=0.48, 95% CI: 0.33-0.70, p&lt;0.0001) and IMvigor210 trials (HR=0.68, 95% CI: 0.51-0.92, p=0.01). In ICB-refractory cancers, B7-H3 expression correlated with high levels of fibroblasts, collagen deposits, and M2 macrophages. Gene set enrichment analysis revealed a positive association between B7-H3 and TGF-β signaling. Genetic deletion of B7-H3 in tumor cells reduced the surface expression of MMP14, a metalloprotease that activates TGF-β. Pan-cancer analysis identified MMP14 as the gene most correlated with B7-H3 (Pearson r=0.69, p&lt;0.0001). TGF-β activation was reduced by 70% in B7-H3 knockout cells compared to wild-type. Loss of B7-H3 led to MMP14 accumulation in lysosomes, resulting in its degradation. We generated a B7-H3 inhibitor, 5D10, which promotes MMP14 degradation and inhibits TGF-β activation. In humanized B7-H3 mouse models, 5D10 significantly reduced TGF-β activation, enhancing CD8 T cell infiltration and impairing tumor growth. Our research identifies B7-H3 as a driver of immune exclusion and ICB resistance. We describe a novel, receptor-independent mechanism where B7-H3 promotes TGF-β activation via stabilization of MMP14. Targeting B7-H3 represents a strategy to modulate the TME, transforming immune-excluded tumors into immune-inflamed states that may respond better to ICB. Citation Format: Fabrice Lucien, Roxane Lavoie, Jack Korleski, Yohan Kim, Bharath Wootla, Liguo Wang, Ava Farrell, Kelly Harper, Martine Charbonneau, Claire Dubois, Igor Frank, Sounak Gupta, John Cheville, Jacob Orme, Stephen Boorjian, Parash Shah, Eugene Kwon, Sean Park, Haidong Dong. The immune checkpoint molecule B7-H3 is a driver of tumor immune exclusion by mediating TGF-β activation [abstract]. In: Proceedings of the AACR IO Conference: Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy; 2025 Feb 23-26; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Immunol Res 2025;13(2 Suppl):Abstract nr B034.
MDR-101-MLK Update: Operational Immune Tolerance Achieved in Living Related HLA-Matched Kidney Transplant Recipients
Akkina, Sanjeev , Piper, James B., Busque, Stéphan , Mai, Martin L., Vera, Michael E. de , Collette, Suzon , Patel, Anup , Stites, Erik, Micsa, Lenuta, Brennan, Daniel C. , Kaufman, Dixon B. , Stegall, Mark D. , Asch, William Stuart , Gaber, A. Osama , Mai, Martin L., Shah, Ashesh P.

Mayo Clinic

Journal of the American Society of Nephrology | February 23, 2025 | Volume: 34 | Issue: 11S | Pages: B3-B3

10.1681/asn.20233411b3a Get It

Guiding Principles for Data Sharing and Harmonization: Results of a Systematic Review and Modified Delphi From the Society of Critical Care Medicine Data Science Campaign
Armaignac, Donna Lee , Heavner, Smith F. , Rausen, Michelle , Zhang, Xiaohan Tanner , Al-Hakim, Tamara, Strekalova, Yulia Levites , Shah, Neel , Remy, Kenneth E. , Manion, Sean T. , Scruth, Elizabeth , Rincon, Teresa , Park, Soojin , Evans, Laura , Ozrazgat‐Baslanti, Tezcan , Murphy, David J. , Engel, Heidi J., Cobb, J. Perren , Clermont, Gilles , Park, Soojin , Laudański, Krzysztof , Haendel, Melissa , Kramer, Andrew A. , Herasevich, Vitaly , Sikora, Andrea , Khanna, Ashish K. , Zimmerman, Jerry J. , Reuter‐Rice, Karin

Mayo Clinic

Critical Care Medicine | February 21, 2025 | Volume: 53 | Issue: 3 | Pages: e619-e631

10.1097/ccm.0000000000006578 | PMID 39982146 Get It

OBJECTIVES: This study aimed to establish a set of guiding principles for data sharing and harmonization in critical care, focusing on the use of real-world data (RWD) and real-world evidence (RWE) to improve patient outcomes and research efficacy. The principles were developed through a systematic literature review and a modified Delphi process, with the goal of enhancing data accessibility, standardization, and interoperability across critical care settings. DATA SOURCES: Data sources included a comprehensive search of peer-reviewed literature, specifically studies related to the use of RWD and RWE in healthcare, guidelines, best practices, and recommendations on data sharing and harmonization. A total of 8150 articles were initially identified through databases such as MEDLINE and Web of Science, with 257 studies meeting inclusion criteria. STUDY SELECTION: Inclusion criteria focused on publications discussing health-related informatics, recommendations for RWD/RWE usage, data sharing, and harmonization principles. Exclusion criteria ruled out non-human studies, case studies, conference abstracts, and articles published before 2013, as well as those not available in English. DATA EXTRACTION: From the 257 selected studies, 322 statements were extracted. After removing irrelevant definitions and off-topic content, 232 statements underwent content validation and thematic analysis. These statements were then consolidated into 24 candidate guiding principles after rigorous review and consensus-building among the expert panel. DATA SYNTHESIS: A three-phase modified Delphi process was employed, involving a conceptualization group, a review group, and a Delphi group. In phase 1, experts identified key themes and search terms for the systematic review. Phase 2 involved validating and refining the prospective guiding principles, while phase 3 employed a Delphi panel to rate principles on acceptability, importance, and feasibility. This process resulted in 24 guiding principles, with high consensus achieved in rounds 2 and 3 on their relevance and applicability. CONCLUSIONS: The systematic review and Delphi process resulted in 24 guiding principles to improve data sharing and harmonization in critical care. These principles address challenges across the data lifecycle, including generation, storage, access, and usage of RWD and RWE. This framework is designed to promote more effective and equitable data practices, with relevance for the development of artificial intelligence-based decision support tools and clinical research. The principles are intended to guide the responsible use of data science in critical care, with emphasis on ethics and equity, while acknowledging the variability of resources across settings.
Efficacy of Colchicine in Stroke Prevention in Patients With Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials
Jain, Hritvik , Ahmed, Raheel, Tariq, Muhammad Daoud , Fox, Sebastian , Passey, Siddhant , Jain, Jyoti , Shah, Siddharth , Cheema, Ameer Haider , Ahmed, Raheel , Ahmed, Mushood , Odat, Ramez M. , Chahal, C. Anwar A.

Mayo Clinic

Cardiology in Review | February 20, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/crd.0000000000000872 | PMID 39976425 Get It

Cardiovascular disease (CVD) is the leading cause of mortality and morbidity worldwide. Low-dose colchicine is a novel and nonstandard management approach for patients with CVDs who are at an increased risk of adverse events. However, few studies have reported the risk of stroke with colchicine, with controversial results. This meta-analysis aimed to compare the efficacy of colchicine and placebo for stroke prevention in patients with CVD. Major electronic databases were screened for randomized controlled trials (RCTs) comparing colchicine and placebo in patients with CVDs from inception to June 2024. Pooled estimates were calculated as risk ratios (RRs) with 95% confidence intervals (CIs) using an inverse-variance random-effects model. Statistical significance was set at P < 0.05. A total of 15 RCTs encompassing 25,116 patients with CVDs were included (12,568: colchicine and 12,548: placebo). The pooled analysis demonstrated a significant reduction in stroke [RR, 0.80 (95% CI, 0.64–0.99); P = 0.04] with colchicine compared with placebo. The risk of all-cause mortality [RR, 1.00 (95% CI, 0.77–1.28)] was comparable between the 2 groups. On subgroup analysis, low-dose colchicine (0.5 mg/day) demonstrated a significantly lower risk of stroke compared with high-dose (>0.5 mg/day) colchicine, which failed to achieve statistical significance. Based on this meta-analysis, colchicine significantly reduced stroke in patients with CVDs compared with placebo. This effect was most significant with low-dose colchicine at 0.5 mg/day. However, no differences were observed in all-cause mortality. Further long-term RCTs are warranted to investigate stroke prevention using colchicine in this population.
Determining Patient Panel Size in Primary Care: A Meta-Narrative Review
McLeod, Heidi , Biazar, Parisa, Mohabbat, Arya B. , Munipalli, Bala , Garofalo, Rachel, Stroebel, Robert J. , Shah, Nilay D. , Angstman, Kurt B. , Farford, Bryan , Horn, Jennifer L. , Allen, Summer V. , Lau, Ana Lucia Chong, Abu Dabrh, Abd Moain , Farah, Wigdan H, McLeod, Heidi M, Munipalli, Bala , Shah, Nilay , Angstman, Kurt B , Presutti, Richard J , Perlman, Adam , Chong Lau, Ana Lucia, Farford, Bryan A , Dabrh, Abd Moain Abu , Farah, Wigdan , Garofalo, Rachel, Presutti, R. John , Perlman, Adam , Lau, Ana Lucia Chong, Prokop, Larry J. , Murad, M. Hassan

Mayo Clinic

Journal of Primary Care & Community Health | February 20, 2025 | Volume: 16 | Issue: No issue available | Pages: No page available

10.1177/21501319251321294 | PMID 39976555 Get It

The optimal patient panel size (PPS) in primary care and the factors determining it remain unclear. We conducted a meta-narrative review of the literature to evaluate factors influencing PPS and assess its association with patient outcomes. A comprehensive search of electronic databases was performed from inception through December 2023, focusing on original studies reporting factors used to determine PPS and related outcomes (eg, clinical outcomes, process measures, and resource utilization). A total of 48 studies were included, identifying 7 key factors influencing PPS. Smaller panels were associated with improved patient satisfaction, continuity of care, and health promotion, while clinical outcomes, utilization, and costs showed minimal impact by PPS. Panel size was primarily associated with patient age, sex, comorbidities, and practice type and structure. Community-based centers typically managed smaller panels, often staffed by female clinicians and serving socioeconomically disadvantaged populations with greater health needs than hospital-based practices. Female clinicians were also independently associated with managing smaller panels, higher quality care indicators, fewer emergency department visits, and improved patient satisfaction. Determining the ideal PPS is a multifaceted process influenced by practice setting, patient demographics, and clinician characteristics. While practice-related factors showed limited association with PPS, patient-reported outcomes were more closely linked to it. Primary care practices should tailor panel sizes to their patient populations, emphasizing a patient-centered approach and ensuring adequate infrastructure support to optimize care delivery.
Comparison Between Dynamic Models for Predicting Response to Corticosteroids in Alcohol‐Associated Hepatitis: A Global Cohort Study
Idalsoaga, Francisco , Díaz, Luis Antonio , Guizzetti, Leonardo , Dunn, Winston , Arnold, Jorge , Ayares, Gustavo , Mortuza, Rokhsana , Mahli, Gurpreet, Islam, Alvi H. , Maiwall, Rakhi , Qian, Steve , Elfeki, Mohamed A. , Ramírez, Carolina , Higuera‐de‐la‐Tijera, Fátima , Al‐Karaghouli, Mustafa , Jalal, Prasun K. , Ibrahim, Mohamad Ali , García‐Tsao, Guadalupe , Havaj, Daniel Ján , Sulejova, Karolina, Shah, Vijay H. , Kamath, Patrick S. , Mehta, Heer , Arnold, Jorge , Ayares, Gustavo , Mortuza, Rokhsana , Sarin, Shiv Kumar , Maiwall, Rakhi , Qian, Steve , Simonetto, Douglas A , Singal, Ashwani K , Elfeki, Mohamed A , Ramirez-Cadiz, Carolina , Cabezas, Joaquín , Ventura Cots, Meritxell , Higuera-De La Tijera, Fatima , Abraldes, Juan G , Jalal, Prasun K , García-Tsao, Guadalupe , Skladaný, Lubomir , Havaj, Daniel J , Kamath, Patrick S , Arrese, Marco , Bataller, Ramon A , Arab, Juan P , Guizzetti, L , Díaz, Luis A , Dunn, Winston , Echavaría, Victor , Zhang, Wei , Simonetto, Douglas A. , Singal, Ashwani K. , Cabezas, Joaquín , Ventura‐Cots, Meritxell , Abraldeṣ, Juan G. , García–Tsao, Guadalupe , Goyes, Daniela , Selčanová, Světlana Adamcová , Rincón, Diego , Arrese, Marco , Arab, Juan Pablo

Mayo Clinic

Alimentary Pharmacology & Therapeutics | February 19, 2025 | Volume: 61 | Issue: 8 | Pages: 1391-1395

10.1111/apt.70024 | PMID 39967231 Get It

ABSTRACTSeveral dynamic models predict mortality and corticosteroid response in alcohol‐associated hepatitis (AH), yet no consensus exists on the most effective model. This study aimed to assess predictive models for corticosteroid response and short‐term mortality in severe AH within a global cohort. We conducted a multi‐national study of patients with severe AH treated with corticosteroids for at least 7 days, enrolled between 2009 and 2019. Dynamic models—Lille‐4, Lille‐7, trajectory of serum bilirubin (TSB), and neutrophil‐to‐lymphocyte ratio (NLR)—were used to estimate 30‐ and 90‐day mortality. Lille‐7 demonstrated the highest accuracy for both 30‐ and 90‐day mortality.